Do you omit anthracyclines in triple positive breast cancer?
Are results of BCIRG-006 trial applicable for patients with triple positive breast cancer or only for those with HER2+?
Answer from: Medical Oncologist at Academic Institution
The BCIRG 006 trial is relevant for all Her2 positive disease, both ER positive and ER negative. Depending on the risk profile of the patient (T2 disease and beyond), I give TCHP x 6 as neoadjuvant therapy per Neosphere and Tryphanema. For T1cN0 disease that is ER negative, I give adjuvant TH x 12, ...